OssDsign

4,10 SEK

-1,33 %

Mindre end 1K følgere

OSSD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-1,33 %
-33,52 %
-55,49 %
-63,89 %
-68,60 %
-68,84 %
-17,11 %
-55,63 %
-76,44 %

OssDsign is a developer and supplier of orthobiological products. The company develops and markets products that support the body's own healing ability, such as OssDsign Catalyst, which is a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company offers its products around the global market. OssDsign was founded in 2011 and is headquartered in Uppsala.

Læs mere
Markedsværdi
453,01 mio. SEK
Aktieomsætning
1,16 mio. SEK
Omsætning
180,16 mio.
EBIT %
-25,95 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
6.5
2026

Delårsrapport Q1'26

9.6
2026

Generalforsamling '26

18.8
2026

Delårsrapport Q2'26

ViserAlle indholdstyper
Eksterne analyser

OssDsign: No drama expected - ABG

* Has already pre-announced sales and EBIT for Q1 * We assume a recovery in sales growth in H2'26e * Q1'26 results due 5 May Q1'26 expectations OssDsign pre-announced preliminary Q1 sales of SEK 36.9m and an expected EBIT range of SEK -12m to -14m for...

OssDsign

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser

OssDsign: Declining sales in Q1 - ABG

* Profit warning ahead of Q1'26 - results due 5 May * 3.6% organic decline in sales (-17% in SEK) * Mid-range EBIT for Q1'26e implies -23% on ABGSCe FY'26e Q1 sales 24% below ABGSCe OssDsign has pre-announced Q1'26 sales of USD 4m, or SEK 37m, and EBIT...

OssDsign
Eksterne analyser

OssDsign: Scaling towards profitability - ABG

* Mixed Q4 but continued operational leverage * Estimates down on adj. EBIT for '26e-'27e (larger loss) * Fair value range down to SEK 7-14 (9-14) Lower sales but improving quality of earnings OssDsign reported a mixed Q4, with sales below expectations...

OssDsign
Eksterne analyser

OssDsign: Lower sales but higher gross margin - ABG

* 24% organic sales growth in Q4 (ABGSCe +27%) Adj. EBIT -2% vs ABGSCe * No change in outlook Q4 results OssDsign reported a mixed set of numbers in Q4 with lower sales but higher gross margin and good cost control. Q4 sales came in at SEK 45.1m (-5%...

OssDsign
Eksterne analyser

OssDsign: FX drag masks solid growth - ABG

* 27% y-o-y organic sales growth in Q4'25e * No change to financial targets expected Q4'25 results due 3 February Q4'25 expectations We believe OssDsign will continue to deliver solid sales growth for Catalyst in the US and pencil in 27% organic growth...

OssDsign
Eksterne analyser

OssDsign: New CEO appointed - ABG

* Mark Waugh appointed new CEO* Relevant background from orthapaedic industry* Supportive for sentiment Getting ready for the next phase OssDsign has appointed Mark Waugh as its new CEO, effective 1 January 2026. Waugh joins from Medacta USA, where he...

OssDsign
Eksterne analyser

OssDsign: Case intact despite slightly slower momentum - ABG

* Major beat on EBIT, but lower sales* Estimates up on adj. EBIT for '25e-'26e (lower loss), yet down for '27e* Fair value range down to SEK 10-17 (11-18)Continued operational leverage despite sales missOssDsign delivered a mixed set of numbers in Q3...

OssDsign
Eksterne analyser

OssDsign: Strong cost control in Q3 - ABG

* 35% organic sales growth in Q3 (ABGSCe +38%)Adj. EBIT +37% vs ABGSCe* No change in outlookQ3 resultsOssDsign reported a mixed set of numbers in Q3 with lower sales but strong cost control and operational leverage. Q3 sales came in at SEK 44.2m (-4%...

OssDsign
Eksterne analyser

OssDsign: Encouraging core despite near-term headwinds - ABG

* 38% y-o-y organic sales growth in Q3'25e* EBIT forecasts cut by 4.0-6.1% for '25e-'27e* Q3'25 results due 4 NovemberQ3'25 expectationsWe expect OssDsign to report Q3 sales of SEK 46.2m and EBIT of SEK -8.5m, implying continued solid sales momentum ...

OssDsign
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.